期刊
PROTEIN & CELL
卷 11, 期 7, 页码 505-517出版社
SPRINGER
DOI: 10.1007/s13238-020-00726-6
关键词
Mycobacterium tuberculosis; EmbB; cryo-EM; ethambutol; cell wall synthesis; arabinoglacatan; arabinosyltransferase; acyl-carrier-protein; drug discovery
类别
资金
- National Key RAMP
- D Program of China [2017YFC0840300]
- Project of International Cooperation and Exchanges NSFC [81520108019]
- Chinese Academy of Sciences [XDB29020000]
- Medical Research Council [MR/S000542/1]
- MRC [MR/S000542/1] Funding Source: UKRI
Inhibition of Mycobacterium tuberculosis (Mtb) cell wall assembly is an established strategy for anti-TB chemotherapy. Arabinosyltransferase EmbB, which catalyzes the transfer of arabinose from the donor decaprenyl-phosphate-arabinose (DPA) to its arabinosyl acceptor is an essential enzyme for Mtb cell wall synthesis. Analysis of drug resistance mutations suggests that EmbB is the main target of the front-line anti-TB drug, ethambutol. Herein, we report the cryo-EM structures of Mycobacterium smegmatis EmbB in its resting state and DPA-bound active state. EmbB is a fifteen-transmembrane-spanning protein, assembled as a dimer. Each protomer has an associated acyl-carrier-protein (AcpM) on their cytoplasmic surface. Conformational changes upon DPA binding indicate an asymmetric movement within the EmbB dimer during catalysis. Functional studies have identified critical residues in substrate recognition and catalysis, and demonstrated that ethambutol inhibits transferase activity of EmbB by competing with DPA. The structures represent the first step directed towards a rational approach for anti-TB drug discovery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据